R2 Dermatology was founded in late 2014 upon the exclusive licensing of technology from Blossom Innovations. The licensed technology was created by scientists R. Rox Anderson, M.D., Director of the Wellman Center of Photomedicine at Massachusetts General Hospital in Boston, a teaching affiliate of Harvard Medical School; Dieter Manstein, M.D., Ph.D., of the Cutaneous Biology Research Center in the Department of Dermatology at Massachusetts General Hospital; and Henry H.L. Chan, M.D., Ph.D., Honorary Clinical Professor, Department of Medicine, The University of Hong Kong and the Visiting Scientist of the Wellman Center for Photomedicine, Massachusetts General Hospital.
We are developing medical devices for the treatment of aesthetic and medical skin conditions, including a skin lightening and skin-tone evening product utilizing “cold technology”. We have received market clearance from the U.S. Food and Drug Administration for our second generation device, the R2 Dermal Cooling System, a cryosurgical instrument intended for use in dermatologic procedures for the removal of benign lesions of the skin.
Our lead investor is Pansend Life Sciences, LLC — a wholly owned indirect subsidiary of HC2 Holdings (NYSE: HCHC). HC2 Holdings is a diversified holding company, which seeks to acquire and grow attractive businesses that generate sustainable free cash flow. In June 2019, we entered into an exclusive distribution agreement with China’s Huadong Medicine Company Limited for the Asia-Pacific Region. In exchange, Huadong made an equity investment in R2 Dermatology to fund our next phase of product and market development.
Our Board and Management Team are experienced in the areas of company formation, in transforming patented ideas into breakthrough procedures and products, and in the creation of compelling premium global brands.